Replies to post #224438 on Biotech Values

[biotech_researcher]

KURA- Bladerunner, KURA is very intriguing, except for this statement:

“Tipifarnib was previously studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets, ****however no molecular mechanism of action had previously been determined that could explain its activity across a range of diverse clinical indications****, including squamous tumors that carry mutant HRAS, as well as in lymphoid, myeloid and solid tumors that do not carry HRAS mutations. “

Without a discovered MOA, do they have a product???